<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666601</url>
  </required_header>
  <id_info>
    <org_study_id>1986-022</org_study_id>
    <secondary_id>TR701-102</secondary_id>
    <nct_id>NCT00666601</nct_id>
  </id_info>
  <brief_title>Microdialysis and Pharmacokinetic Study of TR-701</brief_title>
  <official_title>An Open Label, Single Dose, Microdialysis and Pharmacokinetic Study of TR-701 in Normal Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose
      tissue and skeletal muscle after a single oral dose of 600 mg TR-701
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two parts: a Pilot Study and a Main Study. The Pilot Study
      will be conducted to assess recovery of exogenously administered TR-700 (microbiologically
      active moiety) via microdialysis. In the Main Study, pharmacokinetics of TR-700 will be
      determined in both soft tissues (via microdialysis) and plasma after a single oral dose of
      600 mg TR-701 (prodrug).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2008</start_date>
  <completion_date type="Actual">August 12, 2008</completion_date>
  <primary_completion_date type="Actual">August 12, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subcutaneous tissue concentrations of TR-700</measure>
    <time_frame>Single day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pilot study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 subjects, open lable, microdialysis single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects, open label, single dose of 600 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-700 (active moiety)</intervention_name>
    <description>A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).</description>
    <arm_group_label>Pilot study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 (pro-drug)</intervention_name>
    <description>Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701</description>
    <arm_group_label>Main Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index of 20 to 29 kg/m2

          -  Agree not to consume any products containing tobacco, alcohol, quinine, grapefruit,
             caffeine, or high levels of tyramine

          -  Agree not to use any other medication

          -  Female subjects must be postmenopausal (for at least 6 months), surgically sterile,
             abstinent, or, if sexually active, be practicing an effective method of birth control

        Exclusion Criteria:

          -  History of gastric or duodenal ulcer within 1 year before enrollment

          -  Has known or suspected hypersensitivity or intolerance to heparin, if an indwelling
             cannula (e.g., heparin lock) is used

          -  Recent febrile illness (less than 72 hours before the first intake of study
             medication).

          -  Significant blood loss (300 mL) or donation of blood within the 60 days before the
             Screening visit

          -  Women who are pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harmut Derendorf, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microdialysis</keyword>
  <keyword>Antibiotic</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Torezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

